Hankul (Korea Economic Daily) – August 20, 2026. The Phase III trial of a personalized skin cancer vaccine jointly developed by Moderna and Merck yielded positive results. This outcome is expected to provide new growth impetus for the pharmaceutical industry, and is seen as an important milestone for commercialization of mRNA‑based cancer therapeutics that had been significantly delayed since COVID‑19.
In the experiment, the vaccine was shown to elicit a strong immune response in skin cancer patients while maintaining a favorable safety profile. Accordingly, Moderna and Merck announced plans for future marketing and expanded production, leading to a sharp rise in their shares. Investors rate the drug’s commercialization potential highly, and interest from domestic and overseas markets has increased.
Hankyung Premium 9 (Korea Economic Daily) prohibits copying, duplication, distribution, sharing, capturing, AI learning use or commercial exploitation of this article and related materials without permission. Under copyright law, it states that violations may lead to service restrictions and legal liability.
(This article is a copyrighted work of Korea Economic Daily, and its text cannot be reproduced, distributed, shared, used for AI training or commercial purposes without permission. Violations may result in service restriction and civil or criminal liability.)